E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression

[1]  Qian Wang,et al.  Down-regulation of circPTTG1IP induces hepatocellular carcinoma development via miR-16-5p/RNF125/JAK1 axis. , 2022, Cancer letters.

[2]  F. Laurent,et al.  Head and neck cancer and asbestos exposure , 2022, Occupational and Environmental Medicine.

[3]  Xiangmin Yang,et al.  LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7–H3 in head and neck squamous-cell carcinoma , 2022, Cell Death & Disease.

[4]  Wei‐Chao Chang,et al.  Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial , 2021, BMC cancer.

[5]  G. Stark,et al.  The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage , 2021, Proceedings of the National Academy of Sciences.

[6]  M. Ittmann,et al.  RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. , 2021, Cancer letters.

[7]  Weixin Liu,et al.  MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3 , 2021, Molecular Biotechnology.

[8]  U. Švajger,et al.  Programmed death ligand 1 (PD-L1) plays a vital part in DC tolerogenicity induced by IFN-γ. , 2021, International immunopharmacology.

[9]  J. Fletcher,et al.  E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non–small cell lung cancer , 2021, The Journal of experimental medicine.

[10]  Hao Li,et al.  CMTM4 regulates epithelial–mesenchymal transition and PD‐L1 expression in head and neck squamous cell carcinoma , 2021, Molecular carcinogenesis.

[11]  Lijie Yao,et al.  Toxoplasma gondii Type-I ROP18 Targeting Human E3 Ligase TRIM21 for Immune Escape , 2021, Frontiers in Cell and Developmental Biology.

[12]  A. Deans,et al.  The Fanconi anemia ubiquitin E3 ligase complex as an anti-cancer target. , 2021, Molecular cell.

[13]  Tingjun Hou,et al.  ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation , 2021, Nature Communications.

[14]  Zhigang Huang,et al.  Role of PD‐1/PD‐L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis , 2021, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[15]  Chihao Zhang,et al.  TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination , 2021, Frontiers in Cell and Developmental Biology.

[16]  Jun Ren,et al.  LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR‐129‐3p to activate STAT3 and PD‐L1 , 2021, Cell biology international.

[17]  M. Zhang,et al.  Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. , 2021, Cancer letters.

[18]  Yamil D. Mahmoud,et al.  Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma , 2021, Cancers.

[19]  C. R. Leemans,et al.  Head and neck squamous cell carcinoma , 2020, Nature Reviews Disease Primers.

[20]  Yongzhong Hou,et al.  PD-L1 degradation pathway and immunotherapy for cancer , 2020, Cell Death & Disease.

[21]  T. Ettl,et al.  PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells , 2020, International journal of molecular sciences.

[22]  Shicheng Guo,et al.  Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing TsMHC-II-mediated Immune Recognition. , 2020, The Journal of clinical endocrinology and metabolism.

[23]  M. Qian,et al.  Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages , 2020, Aging.

[24]  B. Seliger,et al.  Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma , 2020, International journal of molecular sciences.

[25]  Yue-Yang Xie,et al.  GC-Derived EVs Enriched with MicroRNA-675-3p Contribute to the MAPK/PD-L1-Mediated Tumor Immune Escape by Targeting CXXC4 , 2020, Molecular therapy. Nucleic acids.

[26]  Xiaofeng Jiang,et al.  E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing , 2020, Theranostics.

[27]  A. Zhou,et al.  Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. , 2020, Pathology, research and practice.

[28]  Qian Ning,et al.  Mechanisms of immune escape in the cancer immune cycle. , 2020, International immunopharmacology.

[29]  M. Hung,et al.  Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma , 2020, Theranostics.

[30]  Ningning Yang,et al.  lncRNA SNHG11 promotes lung cancer cell proliferation and migration via activation of Wnt/β‐catenin signaling pathway , 2020, Journal of cellular physiology.

[31]  D. Fan,et al.  The B7-H4 gene induces immune escape partly via upregulating the PD-1/Stat3 pathway in non-small cell lung cancer. , 2020, Human immunology.

[32]  Murugesan V. S. Rajaram,et al.  Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia , 2020, The Journal of experimental medicine.

[33]  B. O'Malley,et al.  PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma , 2019, British Journal of Cancer.

[34]  Dan Yu,et al.  The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation , 2019, Cell Communication and Signaling.

[35]  R. de Bree,et al.  Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting , 2019, Front. Oncol..

[36]  A. Fucic,et al.  Environmental and behavioural head and neck cancer risk factors. , 2019, Central European journal of public health.

[37]  Gang Chen,et al.  Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression. , 2019, Pathology, research and practice.

[38]  Z. Ronai,et al.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity. , 2019, Trends in molecular medicine.

[39]  M. Zhou,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[40]  M. Yao,et al.  DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up‐regulates PD‐L1 in non‐small‐cell lung cancer , 2019, Experimental cell research.

[41]  Aimin Jiang,et al.  Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment , 2018, Front. Immunol..

[42]  Y. Chu,et al.  The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy , 2018, Journal of Neuroinflammation.

[43]  Ni Zhang,et al.  IFN‐γ‐mediated inhibition of lung cancer correlates with PD‐L1 expression and is regulated by PI3K‐AKT signaling , 2018, International journal of cancer.

[44]  Amy Y. Chen,et al.  Epidemiology and Demographics of the Head and Neck Cancer Population. , 2018, Oral and maxillofacial surgery clinics of North America.

[45]  K. Brown,et al.  Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation , 2015, Cell reports.

[46]  Xiao-rui Li,et al.  Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Original Paper Rnf125 Is a Ubiquitin-protein Ligase That Promotes P53 Degradation , 2022 .

[47]  A. Epstein,et al.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. , 2014, Thyroid : official journal of the American Thyroid Association.

[48]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[49]  D. Payan,et al.  A Novel E3 Ubiquitin Ligase TRAC-1 Positively Regulates T Cell Activation , 2005, The Journal of Immunology.